NeoImmuneTech (NIT), along with its parent company Genexine, has signed an agreement with Roche to perform a Phase Ib/IIa immuno-oncology trial evaluating HyLeukin-7 (IL-7-hyFc) in combination with Tecentriq (atezolizumab) to treat advanced high-risk skin cancers.

The proposed multi-centre open-label trial will cover three cancer types, including melanoma, Merkel cell carcinoma and cutaneous squamous cell carcinoma.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The trial will be led by NIT and the Immune Oncology Network (ION), and will aim to investigate safety and anti-tumour activity of HyLeukin-7 in combination with Tecentriq in around 70 patients with anti-PD-(L)1 naïve or refractory high-risk skin cancers.

“HyLeukin-7 has shown in multiple studies to substantially increase the total body complement of T cells with little toxicity.”

The trial is expected to begin by the second half of this year and will be conducted across the US and possibly additional countries.

Fred Hutchinson Cancer Research Center Immune Oncology Network director Martin Cheever said: “HyLeukin-7 has shown in multiple studies to substantially increase the total body complement of T cells with little toxicity.

“HyLeukin-7 is designed to be effective when used in concert with a variety of different immunotherapy regimens, including the combination with anti-PD-(L)1 that is being tested in this trial.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

HyLeukin-7 is a T cell amplifier, featuring a covalently linked homodimer of engineered Interleukin-7 (IL-7) molecule, biologically fused with the proprietary long-acting platform hyFc.

The solution is currently under development as an ‘IO enabling’ therapy to harness T cell immunity in combination with other cancer treatments, especially with anti-PD-(L)1 agents or chemo/radiotherapy.

Tecentriq (atezolizumab), a registered product of Roche Group member Genentech, is a PD-L1 checkpoint inhibitor.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact